Functions of the von Hippel-Lindau tumour suppressor protein

Journal of Internal Medicine

Volumn 243, Issue 6, 1998, Pages 535-539

  Kaelin, W G ^a   Iliopoulos, O ^a   Lonergan, K M ^a   Ohh, M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Elongins; Tumour suppressor gene; Tumour suppressor protein; Von Hippel Lindau disease

Indexed keywords

GENE PRODUCT; VASCULOTROPIN RECEPTOR;

CONFERENCE PAPER; CYTOPLASM; DISEASE PREDISPOSITION; GENE INDUCTION; HUMAN; HYPOXIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; RETINOBLASTOMA; RISK FACTOR; TUMOR SUPPRESSOR GENE; VON HIPPEL LINDAU DISEASE;

EID: 7144256497     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1998.00335.x     Document Type: Conference Paper

References (46)

1. McKusick VA. Mendelian Inheritance in Man. Baltimore and London: The Johns Hopkins University Press. 1992
2. Manski T, Heffner D, Glenn G, Patronas N, Pikus A, Katz D et al. Endolymphatic sac tumours - a source of morbid hearing loss in von Hippel-Lindau disease. JAMA 1997; 277: 1461-6.
3. Linehan WM, Lerman MI, Zbar B. Identification of the von Hippel-Lindau (VHL) gene. JAMA 1995; 273: 564-70.
4. Latif F, Tory K, Gnarra J, Yao M, Dun F-M, Orcutt ML et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260: 1317-20.
5. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM et al. Germline mutations in the von Hippel-Lindau (VHL) gene in families from North America, Europe, and Japan. Human Mutations 1996; 8: 348-57.
6. Renbaum P, Duh F-M, Latif F, Zbar B, Lerman M, Kuzmin I. Isolation and characterization of the full-length 3′ untranslated region of the human von Hippel-Lindau tumour suppressor gene. Hum Genet 1996; 98: 666-71.
7. Iliopoulos O, Kibel A, Gray S. Kaelin WG. Tumor suppression by the human von Hippel-Lindau gene product. Nature Med 1995; 1: 822-6.
8. Nagashima Y, Miyagi Y, Udagawa K, Taki A, Misugi K, Sakai N et al. Von Hippel-Lindau tumour suppressor gene. Localization of expression by in situ hybridization. J Pathol 1996; 180: 271-4.
9. Corless CL, Kibel A, Iliopoulos O, Kaelin WGJ. Immunostaining of the von Hippel-Lindau gene product (pVHL) in normal and neoplastic human tissues. Human Path 1997; 28: 459-64.
10. Los M, Jansen GH, Kaelin WG, Lips CJM, Blijham GH, Voest EE. Expression pattern of the von Hippel-Lindau protein in human tissues. Lab Invest 1996; 75: 231-8.
11. Kessler P, Vasavada S, Rackley R, Stackhouse T, Duh F, Latif F et al. Expression of the von Hippel-Lindau tumour-suppressor gene, VHL, in human fetal kidney and during mouse embryogenesis. Mol Med 1995; 1: 457-66.
12. Richards F, Schofield P, Fleming S, Maher E. Expression of the von Hippel-Lindau disease tumour suppressor gene during human embryogenesis. Human Mol Genet 1996; 5: 639-44.
13. Iliopoulos O, Kaelin WG. The molecular basis of von Hippel-Lindau disease. Mol Med 1997; 3: 289-93.
14. Lubensky IA, Gnarra JR, Bertheau P, Walther MM, Linehan WM, Zhuang Z. Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Path 1996; 149: 2089-94.
15. Zhuang Z, Bertheau P, Emmert-Buck M, Liotta L, Gnarra J, Linehan W, Lubensky I. A microscopic dissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Path 1995; 146: 620-25.
16. Kinzler K, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996; 87: 159-70.
17. Duan DR, Humphrey JS, Chen DYT, Weng Y, Sukegawa J, Lee S et al. Characterization of the VHL tumour suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci (USA) 1995; 92: 6495-9.
18. Gao J, Naglich JG, Laidlaw J, Whaley JM, Seizinger BR, Kley N. Cloning and characterization of a mouse gene with homology to the human von Hippel-Lindau disease tumour suppressor gene: implications for the potential organization of the human von Hippel-Lindau disease gene. Cancer Res 1995; 55: 743-7.
19. Gnarra JR, Zhou S, Merrill MJ, Wagner J, Krumm A, Papavassiliou E et al. Post-transcriptional regulation of vascular endothelial growth factor mRNA by the VHL tumour suppressor gene product. Proc Natl Acad Sci USA 1996; 93: 10589-94.
20. Lee S, Chen DYT, Humphrey JS, Gnarra JR, Linehan WM, Klausner RD. Nuclear/cytoplasmic localization of the von Hippel-Lindau tumour suppressor gene product is determined by cell density. Proc Natl Arad Sci USA 1996; 93: 1770-75.
21. Kibel A, Iliopoulos O, DeCaprio JD, Kaelin WG. Binding of the von Hippel-Lindau tumour suppressor protein to elongin B and C. Science 1995; 269: 1444-6.
22. Duan DR, Pause A, Burgress W, Aso T, Chen DYT, Garrett KP et al. Inhibition of transcriptional elongation by the VHL tumour suppressor protein. Science 1995; 269: 1402-6.
23. Aso T, Lane WS, Conaway JW, Conaway RC. Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 1995; 269: 1439-43.
24. Kishida T, Stackhouse TM, Chen F, Lerman MI, Zbar B. Cellular proteins that bind the von Hippel-Lindau disease gene product: mapping of binding domains and the effect of missense mutations. Cancer Res 1995; 55: 4544-8.
25. Tsuchiya H, Iseda T, Hino O. Identification of a novel protein (VBP-1) binding to the von Hippel-Lindau (VHL) tumour suppressor gene product. Cancer Res 1996; 56: 2881-5.
26. Aso T, Haque D, Barstead R, Conaway R, Conaway J. The inducible elongin A elongation activation domain: structure, function and interaction with elongin BC complex. EMBO J 1996; 15: 101-10.
27. Wizigmann-Voos S, Breier G, Risau W, Plate K. Up-regulation of vascular endothelial growth factor and its receptors in von Hippel-Lindau disease-associated and sporadic haeman-gioblastomas. Cancer Res 1995; 55: 1358-64.
28. Berse B, Brown L, Livingston V, Dvorak H, Senger D. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues. macrophages, and tumours. Mol Biol Cell 1992; 3: 211-20.
29. Takahashi A, Sasaki H, Kim S, Tobisu K, Kakizoe T, Tsukamoto T et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994; 54: 4233-7.
30. Sato K, Terada K, Sugiyama T, Takahashi S, Saito M, Moriyama M et al. Frequent overexpression of vascular endothelial growth factor gene in human renal cell carcinoma. Tohoku J Exp Med 1994; 173: 355-60.
31. Golde DW, Hocking WG. Polycythemia: mechanisms and management. Ann Intern Med 1981; 95: 71-87.
32. Goldberg MA, Schneider TJ. Similarities between the oxygensensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994; 269: 4355-9.
33. Iliopoulos O, Jiang C, Levy AP, Kaelin WG, Goldberg MA. Negative Regulation of Hypoxia-Inducible Genes by the von Hippel-Lindau Protein. Proc Natl Acad Sci USA 1996; 93: 10595-9.
34. Siemeister G, Weindel K, Mohrs K, Barleon B, Martiny-Baron G, Marme D. Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumour suppressor Protein. Cancer Res 1996; 56: 2299-301.
35. Gnarra JR, Duan DR, Weng Y, Humphrey JS, Chen DYT, Lee S et al. Molecular cloning of the von Hippel-Lindau tumour suppressor gene and its role in renal cell carcinoma (Review). Biochimica et Biophysica Acta 1996; 1242: 201-10.
36. Pause A, Lee S, Worrell RA, Chen DYT, Burgess WH, Linehan WM, Klausner RD. The von Hippel-Lindau tumour-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci USA 1997; 94: 2156-61.
37. Kipreos ET, Lander LE, Wing JP, He WW, Hedgecock EM. cul-1 is required for cell cycle exit in C. elegans and identifies a novel gene family. Cell 1996; 85: 829-39.
38. Jackson PK. Cell cycle: cull and destroy. Current Biol 1996; 6: 1209-12.
39. Bai C, Sen P, Hofmann K, Ma L, Goebl M, Harper JW, Elledge SJ. SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box. Cell 1996; 86: 263-74.
40. Levy AP, Levy NS, Iliopoulos O, Jiang C, Kaelin WG, Goldberg MA. Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumour suppressor gene. Kidney Int 1997; 51: 575-8.
41. Vaheri A, Alitalo K, Hedman K, Keski-Oja J, Kurkinen M, Wartiovaara J. Fibronectin and the pericellular matrix of normal and transformed adherent cells. Ann NY Acad Sci 1978; 312: 343-53.
42. Chen L, Burridge K, Murray A, Walsh M, Copple C, Bushnell A et al. Modulation of cell surface glycocalyx: studies on large, external. transformation-sensitive protein. Ann NY Acad Sci 1978; 312: 366-81.
43. Hynes R, Ali I, Destree A, Mautner V, Perkins M, Senger D et al. A large glycoprotein lost from the surfaces of transformed cells. Ann NY Acad Sci 1978; 312: 317-42.
44. Lipkin G, Knecht M, Rosenberg M. Glycoprotein-containing factor that mediates contact inhibition of growth. Ann NY Acad Sci 1978; 312: 382-91.
45. Giancotti FG, Ruoslahti E. Elevated levels of the a5b1 fibronectin receptor suppress the transformed phenotype of Chinese hamster ovary cells. Cell 1990; 60: 849-59.
46. Pasqualini R, Bourdoulous S, Koivunen E, Woods Jr V, Ruoslahti E. A polymeric form of fibronectin has antimetastatic effects against multiple tumour types. Nature Med 1996; 2: 1197-203.